Viatris (VTRS) EBITDA (2019 - 2026)
Viatris (VTRS) posted EBITDA of $6.3 million for Q2 2026, up 107.9% on a QoQ basis from -$79.7 million in Q1 2026, and down 97.3% year-over-year from $233.0 million in Q2 2025.
Analysis
Viatris (VTRS) EBITDA (2019 - 2026) Analysis & Trends
Viatris has reported EBITDA for 8 years, with the latest figure at $6.3 million in Q2 2026.
- On a quarterly basis, EBITDA fell 97.3% year-over-year to $6.3 million in Q2 2026; TTM through Jun 2026 was -$87.3 million, a 96.65% increase from a year earlier, with the FY2025 full-year figure at -$2.7 billion, down 26467.33% from the prior year.
- EBITDA was $6.3 million for Q2 2026 at Viatris, up from -$79.7 million in the prior quarter.
- The five-year high for EBITDA was $707.4 million in Q1 2022, with the low at -$2.9 billion in Q1 2025.
- Average EBITDA over 5 years is -$19.2 million, with a median of $191.4 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2025: EBITDA soared 1247.91% in 2022, then tumbled 1513.54% in 2025.
- Over 5 years, EBITDA stood at -$201.3 million in 2022, then plunged by 125.78% to -$454.5 million in 2023, then soared by 60.44% to -$179.8 million in 2024, then declined by 7.17% to -$192.7 million in 2025, then surged by 103.27% to $6.3 million in 2026.
- The last three EBITDA figures came in at $6.3 million (Q2 2026), -$79.7 million (Q1 2026), and -$192.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.60 Bn | 38.95 Bn | 2.15 Bn | -231.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 6.30 Mn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 39.97 Mn |
| 4 | Amneal Pharmaceuticals | 5.46 Bn | 5.33 Bn | 334.51 Mn | 129.77 Mn |
| 5 | Bausch Health Companies | 2.36 Bn | 520.75 Mn | 2.10 Bn | 740.00 Mn |
| 6 | Alvotech | 1.51 Bn | 1.37 Bn | 2.56 Mn | -73.42 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 40.46 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 39.73 Mn |
| 9 | Fennec Pharmaceuticals | 411.09 Mn | 369.84 Mn | 17.15 Mn | 1.74 Mn |
| 10 | RedHill Biopharma | 181.39 Mn | 181.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.30 Mn |
| Mar 31, 2026 | -79.70 Mn |
| Dec 31, 2025 | -192.70 Mn |
| Sep 30, 2025 | 178.80 Mn |
| Jun 30, 2025 | 233.00 Mn |
| Mar 31, 2025 | -2.88 Bn |
| Dec 31, 2024 | -179.80 Mn |
| Sep 30, 2024 | 225.90 Mn |
| Jun 30, 2024 | -239.90 Mn |
| Mar 31, 2024 | 203.90 Mn |
| Dec 31, 2023 | -454.50 Mn |
| Sep 30, 2023 | 451.70 Mn |
| Jun 30, 2023 | 369.20 Mn |
| Mar 31, 2023 | 399.80 Mn |
| Dec 31, 2022 | -201.30 Mn |
| Sep 30, 2022 | 560.10 Mn |
| Jun 30, 2022 | 548.70 Mn |
| Mar 31, 2022 | 707.40 Mn |
| Dec 31, 2021 | -77.60 Mn |
| Sep 30, 2021 | 357.60 Mn |